About SCI America
SCI America is a collaborative organization, working with an array of leading U.S. and global entities that share complementary missions to advance the success of the chemical industry. We support the industry by offering scholarships and internships to underserved and Historically Black Colleges and Universities chemistry and chemical engineering students; by providing an annual forum, Innovation Day, for R&D scientists of member companies to exchange research ideas and connect with others in their fields; and by recognizing technical and industry achievement through our awards
SCI America Joins FOSSI Program
The Future of STEM Scholars Initiative provides $40,000 scholarships to graduating high school seniors pursuing preferred STEM degrees at Historically Black Colleges and Universities.
Philadelphia, PA | April 25, 2022– The Society of Chemical Industry America (SCI America) today announced its engagement in the Future of STEM Scholars Initiative (FOSSI), the chemical industry’s collaborative equity, diversity, and inclusion initiative aimed at creating pathways for more underrepresented groups to enter and succeed in science, technology, education, and math (STEM) careers in the chemical industry.
FOSSI is a national scholarship program which provides incoming college freshman $40,000 scholarships and connects them to leadership development, mentoring, and internship opportunities at sponsoring companies. FOSSI creates lasting and meaningful relationships between students and sponsors, helping to create a diverse pipeline of future workforce talent. FOSSI has an ambitious goal of supporting 1,000 scholars through 2025, at an investment of nearly $50 million.
SCI America will sponsor two scholars over the next four years, joining a growing list of organizations who together have raised more than $16 million.
“SCI America is proud to expand our annual scholars program to include two FOSSI scholarships through 2026. Our membership is strongly committed to increasing access for all students to the STEM field and FOSSI’s program is indeed the standard for promoting inclusion of Black students in the chemical sector,” said SCI America’s Chair John Paro, Chairman and CEO of Hallstar.
“FOSSI brings together the industry’s collective might to make a significant impact on the future of the chemical industry. As a former SCI America Executive Committee member, I am thrilled that they will be supporting FOSSI scholars,” says FOSSI Chairman Mark Vergnano. “We are grateful to SCI America for their support in this important initiative and look forward to working with their team to create opportunities and pathways for success for these deserving scholars.”
About the Future of STEM Scholars Initiative
The Future of STEM Scholars Initiative was founded in 2020 by the American Chemistry Council, the American Institute of Chemical Engineers, The Chemours Company, and the HBCU Week Foundation. FOSSI is a national chemical industry-wide program which provides scholarships to students pursuing degrees in relevant science, technology, engineering, and mathematics (STEM) at Historically Black Colleges and Universities (HBCUs), helping to eliminate financial barriers for historically under-represented groups. Sponsored by chemical manufacturers and related industry stakeholders, FOSSI provides scholarship recipients $10,000 per year for four years and connects these students to leadership development, mentoring, and internship opportunities at participating companies. Learn more at FutureofSTEMscholars.org.
Dennis Liotta, PhD, to receive 2022 Perkin Medal
Emory University’s Dennis Liotta to Receive Prestigious 2022 Perkin Medal
Dr. Dennis Liotta to be honored by the Society of Chemical Industry on September 13, 2022 PHILADELPHIA, March 15, 2022 – The Society of Chemical Industry (SCI) America announced today that Dennis Liotta, PhD, Emory University, will be awarded the 2022 Perkin Medal at an award ceremony in Philadelphia, PA on September 13, 2022.
“Dr. Liotta’s work has directly impacted the lives of millions of individuals around the world living with HIV/AIDS. His discovery of emtricitabine and lamivudine was pivotal in changing the tide of the AIDS epidemic,” said John Paro, Chair and CEO of Hallstar and Chair of SCI America. “In the past 20 years he has continued to make contributions to the biopharmaceutical sector, with his research playing a role in many lifesaving therapies.”
The Perkin Medal Selection Committee, consisting of the Chairs or Presidents of the American Chemical Society, the American Institute of Chemical Engineers, the Science History Institute, and the Society of Chemical Industry, noted Dr. Liotta’s groundbreaking research in the biopharmaceutical space and work with antivirals, in relation to AIDS/HIV and other viruses such as Hepatitis B and SARS-CoV2. His founding of both Emory Institute for Drug Development (EIDD) and the Drug Innovation Ventures at Emory (DRIVE) has resulted in a remarkable output of research and a mentorship pipeline. The Committee also noted his many commercial accomplishments to bring drugs to market through his various companies. His most recent remarkable accomplishment is the approval of molnupiravir, a drug that was developed by EIDD/DRIVE for combating multiple viral diseases and that has recently received Emergency Use Authorization (EUA) in the US and UK for treating COVID-19 patients.
Dr. Liotta will receive the medal at a dinner in his honor on September 13, 2022 at the Hyatt at the Bellevue in Philadelphia.
# # #
About Dennis Liotta
Dennis Liotta, PhD, serves as Executive Director of the Emory Institute for Drug Development and Samuel Candler Dobbs Professor in the Department of Chemistry at Emory University. Dr. Liotta is recognized as one of the premier discoverers of novel therapeutics in the United States, having been the inventor of record for several clinically important antivirals and associated with the invention of ten FDA approved therapeutics.
Dr. Liotta’s research has focused on the discovery and development of antiviral, anticancer, and anti-inflammatory therapeutic agents. He is one of the leaders of the Emory research team that discovered the antiviral drug, Emtriva (emtricitabine), which was approved for treating HIV in July 2003 and is now used by more than 90 percent of HIV/AIDS patients in the United States, and by thousands more around the globe. Emtriva is a component of the triple combination therapy, Atripla, which is now universally accepted as the drug combination of choice for treating HIV infected patients. In addition, he is the inventor of record for several antivirals, including Epivir, Reverset, Racivir, and Elvucitabine. Other medicinal inventions generated by Liotta’s lab over the years include therapies for everything from cancer and rheumatoid arthritis to hepatitis B.
Dr. Liotta joined Emory in 1976. Since that time, he has authored over 230 research publications and more than 70 issued US patents. Dr. Liotta has also supervised numerous postdoctoral and graduate students and has received several teaching awards, including Emory University’s Thomas Jefferson Award, the highest faculty honor given at Emory. He is a fellow of both the American Association for the Advancement of Science and the American Chemical Society. Dr. Liotta was elected to the National Academy of Inventors in 2014 and the Medicinal Chemistry Hall of Fame in 2010. Dr. Liotta also is the co-director of the Republic of South Africa Drug Discovery Training Program and a member of the Discovery and Developmental Therapeutics Research Program at Winship.
Kevin Maloney, PhD, to receive 2022 Gordon E. Moore Medal
Chemist from Merck’s Process Research Lab is recognized for his leadership pharmaceutical manufacturing processes to be honored on September 13, 2022
PHILADELPHIA, April 18, 2022 – The Society of Chemical Industry (SCI) America announced today that Kevin Maloney, PhD, is the recipient of the 19th annual Gordon E. Moore medal. SCI established the Gordon E. Moore Medal to recognize early-career success in innovation, as reflected both in market impact and improvement to quality of life. Dr. Maloney, research chemist at Merck, known as MSD outside the United States and Canada, will be presented the award at Innovation Day, hosted jointly by SCI and the Science History Institute on September 13, 2022 at the Science History Institute in Philadelphia.
“Dr. Maloney’s research at Merck has already made important impacts on human health,” said John Paro, Chair and CEO of Hallstar and Chair of SCI America. “His work is having a direct impact on people’s daily quality of life and his research has laid the groundwork for a more sustainable and efficient future for pharmaceutical chemistry.”
Dr. Maloney is known for leading three key innovative new technologies while at Merck, including using chemocatalysis in the production of ceftolozane synthesis, making the process more efficient in terms of waste and production time; using flow chemistry to synthesize gefapixant, Merck’s second introduction of a plug flow reactor for large scale manufacture; and the pioneering use of biocatalysis to engineer enzymes for use in the synthesis of islatravir. These innovations have led to more sustainable pharmaceutical manufacturing processes at Merck.
“Dr. Maloney has demonstrated an unparalleled passion for pushing the frontiers of chemistry and reimagining how those innovations impact the way we manufacture our therapies,” said Rebecca Ruck, Assistant Vice President, Process Research and Development, Merck.
# # #
About Kevin Maloney
Dr. Kevin M. Maloney is Executive Director, Process Chemistry, Merck Research Laboratories. Since joining Merck in 2007, he has held positions of increasing responsibility within the Process Research & Development organization. Throughout his time at Merck, he has successfully pursued a series of breakthrough innovations using enabling technologies in synthetic organic chemistry to develop green, sustainable, and cost-effective manufacturing processes for active pharmaceutical ingredients (API).
Dr. Maloney’s leadership has been instrumental in driving innovation on both the current and future pipeline and developing the next generation of talent. His teams have employed chemocatalysis, flow chemistry and biocatalysis to develop green and sustainable commercial manufacturing processes for ceftolozane sulfate (the antibiotic in ZerbaxaTM), gefapixant (an investigational candidate for the treatment of chronic cough), and islatravir (an investigational candidate for the treatment for HIV). Through his leadership, a revolutionary advance in nucleoside synthesis for islatravir was developed utilizing an enzymatic cascade process that has changed the way chemists think about making nucleosides. Building on this innovative approach, a green and sustainable three-step process utilizing a novel biocatalytic cascade was developed for molnupiravir (LagevrioTM). Additionally, Dr. Maloney has collaborated with his colleague, Dr. Patrick Fier, to establish a research program developing new synthetic methodologies focused on a novel hydroxylation reaction to prepare complex phenols (Maloney-Fier Hydroxylation) and on transformation of sulfonamides for late-stage functionalization, resulting in five publications in top-tier journals.
As a self-professed green chemistry champion, Dr. Maloney leads Merck’s Green & Sustainable Science Team, which focuses on reinforcing the role of green chemistry in pharmaceutical manufacturing through external and internal advocacy. In this role he has organized the annual Merck Green & Sustainable Science symposium and established API sustainability targets for small molecules as part of the Merck corporate sustainability goals. Over the past five years, Merck has received five consecutive Environmental Protection Agency Green Chemistry Challenge Awards. Lastly, Dr. Maloney is influential in the science community with more than 45 publications, several invited lectures and was recently awarded the inaugural ACS Division of Organic Chemistry Mid-Career Industrial Investigator Award.
Dr. Maloney holds a PhD from the Massachusetts Institute of Technology under Prof. Rick Danheiser, and a BS from Stetson University.
SCI America supports the chemical enterprise with three signature events each year: the Chemical Industry Medal ceremony and dinner, the Perkin Medal ceremony and dinner, and Innovation Day and the honoring of the Gordon E. Moore Medal.
September 13, 2022
Innovation Day at Science History Institute in Philadelphia, with a virtual component
Innovation Day is open to members of SCI America and is developed by the Innovation Day Steering Committee, made up of CTOs of member companies. Each year the Steering Committee creates programming highlighting the latest technologies and collaborations across the chemical enterprise. Cohosted with the Science History Institute since 2004, Innovation Day features the Warren G. Schlinger Symposium and the awarding of the Gordon E. Moore Medal, along with several panels and a poster session.
September 13, 2022
INNOVATION DAY AT SCIENCE HISTORY INSTITUTE IN PHILADELPHIA
An in-person and virtual conference open to member companies.
March 7, 2023
Chemical Industry Medal Dinner at the Plaza Hotel in New York
Join us as we celebrate a chemical industry leader at this black-tie affair.